Cue Biopharma (CUE) Expected to Post Quarterly Earnings on Wednesday

Cue Biopharma (NASDAQ:CUE) is projected to issue its Q3 2026 resultson Wednesday, November 11th. Analysts expect Cue Biopharma to post earnings of ($2.2433) per share and revenue of $1.03 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Cue Biopharma (NASDAQ:CUE) last announced its earnings results on Friday, August 14th. The company reported ($24.14) EPS for the quarter, missing analysts’ consensus estimates of ($1.69) by ($22.45). The firm had revenue of $7.88 million during the quarter, compared to the consensus estimate of $3.00 million. Cue Biopharma had a negative return on equity of 620.06% and a negative net margin of 435.83%. On average, analysts expect Cue Biopharma to post ($21.79) EPS for the current fiscal year and ($8.70) EPS for the next fiscal year.

Cue Biopharma Price Performance

CUE stock opened at $20.86 on Wednesday. The firm has a 50-day simple moving average of $25.39 and a two-hundred day simple moving average of $118.82. Cue Biopharma has a one year low of $4.97 and a one year high of $45.50.

Insider Buying and Selling

In other Cue Biopharma news, VP Michael Vincent Meluzio sold 5,628 shares of the stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $30.09, for a total value of $169,346.52. Following the completion of the sale, the vice president directly owned 48,961 shares in the company, valued at approximately $1,473,236.49. This trade represents a 10.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Shao-Lee Lin sold 40,000 shares of the stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $27.10, for a total value of $1,084,000.00. Following the completion of the sale, the chief executive officer owned 724,253 shares of the company’s stock, valued at approximately $19,627,256.30. This trade represents a 5.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 86,790 shares of company stock worth $2,430,815 in the last ninety days. 14.56% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on CUE shares. Weiss Ratings downgraded shares of Cue Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, August 27th. Wall Street Zen cut shares of Cue Biopharma from a “sell” rating to a “strong sell” rating in a research report on Saturday, September 26th. B. Riley Financial began coverage on shares of Cue Biopharma in a research report on Friday, September 18th. They set a “buy” rating and a $83.00 target price for the company. Finally, Zacks Research upgraded shares of Cue Biopharma to a “hold” rating in a research note on Monday, September 21st. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $83.00.

About Cue Biopharma

Cue Biopharma, Inc is a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer and other serious diseases. The company’s approach is designed to selectively activate a patient’s own T cells against disease-associated antigens while minimizing broad immune-system activation.

Cue Biopharma’s product candidates are based on its Immuno-STAT (Selective Targeting and Alteration of T cells) platform, which uses biologic molecules intended to engage specific T-cell receptors and deliver immune-modulating signals.